The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's OZEMPIC Approval Heat Up the Chronic Kidney disease Therapeutic market | DelveInsight The FDA's recent approval of OZEMPIC ...

EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD ... the FDA’s recent label expansion of Novo Nordisk’s Ozempic® to include CKD benefits, reinforcing the drug ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

Ozempic, the GLP-1 drug initially ... was recently OK’d to help reduce risks linked to chronic kidney disease (CKD). That’s according to Novo Nordisk, a pharmaceutical company and maker ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease. Southeastern Grocer's president and CEO ...

Semaglutide reduced the risk of kidney disease worsening ... Medical & Regulatory Affairs at Novo Nordisk. Ozempic is also indicated as an adjunct to diet and exercise to improve glycemic control ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged ...

(Bloomberg) -- Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use.